Clinical trials: Hypertension, Pulmonary
Pulmonary Hypertension
Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
The purpose of this study is to gain information on safety and efficacy from Korean patients who starting Ventavis treatment by observational method.
- Trial name
- NCT01062282
- Testing
- Iloprost (Ventavis BAYQ6256)
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Trial name
- NCT06581159
- Testing
- HS135
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- 35Pharma Inc., a GSK company
Healthy
Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl
This is an open-label study to evaluate the PK and excretion of a single oral dose of [14C]-rodatristat ethyl. The study will consist of: Screening evaluations (within 29 days prior to dosing); a treatment phase (from dosing…
- Trial name
- NCT05006118
- Testing
- Radio-labeled rodatristat ethyl 600 mg
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Altavant Sciences GmbH
Cardiovascular Diseases, Right Heart Failure
Repository of Phase Signals for Pulmonary Hypertension Algorithm Development
This study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the Phase Signal Recorder (PSR) prior to Right Heart Cath (RHC).
- Conditions
- Cardiovascular Diseases, Right Heart Failure, Cardiac Disease
- Trial name
- IDENTIFY - PH (NCT04031989)
- Testing
- CorVista Capture
- Where
- 17 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Analytics For Life
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
- Trial name
- NCT05938946
- Testing
- L608 Inhalation Solution
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Pulmonary Arterial Hypertension
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).
- Trial name
- NCT01553721
- Testing
- udenafil
- Where
- 9 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Dong-A ST Co., Ltd.
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e.
- Trial name
- NCT02246348
- Testing
- Doppler ultrasound
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Echosense Ltd.
Pulmonary Hypertension
Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension
The development of disease-targeted drugs for the treatment of pulmonary arterial hypertension (PAH) has significantly improved within the last years.
- Trial name
- BOTA-PAH (NCT03139084)
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human…
- Trial name
- TRUST-1 (NCT00494533)
- Testing
- Remodulin (treprostinil sodium)
- Where
- 14 sites in India
- Volunteers
- 45 people
- Sponsor
- United Therapeutics
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Juvenile Idiopathic Arthritis
Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
This study is designed to analyze the frequency and incidence rate of pulmonary complications in JIA participants who received biological DMARDs and non-biologic DMARDs.
- Trial name
- NCT02784808
- Testing
- Biological DMARDs, Non-Biologic DMARDs
- Volunteers
- 4,557 people
- Sponsor
- Hoffmann-La Roche
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Pulmonary Fibrosis, Pulmonary Hypertension
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's…
- Trial name
- NCT05356052
- Testing
- INOpulse
- Sponsor
- Bellerophon
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Prospective, multi-center, open-label, single-arm, Phase 3b extension study of macitentan in patients with PAH. To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment…
- Trial name
- NCT02112487
- Testing
- Macitentan
- Where
- 32 sites in France, Italy and 1 more
- Volunteers
- 88 people
- Sponsor
- Actelion
Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure
Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertension
Title : A multicenter clinical trial of the portable nitric oxide generation and delivery system (INOwill N200) for the treatment of neonatal hypoxic respiratory failure complicated by pulmonary hypertension Investigational…
- Trial name
- iNOwill Neonat (NCT07837921)
- Testing
- Nitric Oxide Generator and Delivery System
- Volunteers
- 50 people
- Sponsor
- Novlead Inc.